Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1955 1
1958 1
1959 1
1964 1
1967 1
1978 1
1993 1
1995 2
1996 4
1997 3
1998 18
1999 25
2000 37
2001 55
2002 62
2003 73
2004 86
2005 132
2006 219
2007 411
2008 729
2009 1127
2010 1372
2011 1603
2012 1762
2013 1880
2014 2050
2015 2276
2016 2247
2017 2280
2018 2269
2019 2383
2020 2341
2021 178
Text availability
Article attribute
Article type
Publication date

Search Results

22,471 results
Results by year
Filters applied: . Clear all
Page 1
IL-17 Signaling: The Yin and the Yang.
Amatya N, Garg AV, Gaffen SL. Amatya N, et al. Trends Immunol. 2017 May;38(5):310-322. doi: 10.1016/j.it.2017.01.006. Epub 2017 Feb 20. Trends Immunol. 2017. PMID: 28254169 Free PMC article. Review.
Interleukin (IL)-17 is the founding member of a novel family of inflammatory cytokines. While the proinflammatory properties of IL-17 are key to its host-protective capacity, unrestrained IL-17 signaling is associated with immunopa
Interleukin (IL)-17 is the founding member of a novel family of inflammatory cytokines. While the proinflammatory prope
IL-17: overview and role in oral immunity and microbiome.
Abusleme L, Moutsopoulos NM. Abusleme L, et al. Oral Dis. 2017 Oct;23(7):854-865. doi: 10.1111/odi.12598. Epub 2016 Dec 27. Oral Dis. 2017. PMID: 27763707 Free PMC article. Review.
Interleukin-17 (IL-17) is a multifaceted cytokine with diverse roles in both immune protection and also immunopathology. ...The current review introduces basic aspects of IL-17 biology and examines the protective and pathogenic roles of
Interleukin-17 (IL-17) is a multifaceted cytokine with diverse roles in both immune protection and also immunopa
The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond.
Brembilla NC, Senra L, Boehncke WH. Brembilla NC, et al. Front Immunol. 2018 Aug 2;9:1682. doi: 10.3389/fimmu.2018.01682. eCollection 2018. Front Immunol. 2018. PMID: 30127781 Free PMC article. Review.
Today, the belief that Th17 cells mediate psoriasis is moving to the concept of psoriasis as an IL-17A-driven disease. New questions arise at the horizon, given that IL-17A is part of a newly described family of cytokines, which has five distinct homologous: IL
Today, the belief that Th17 cells mediate psoriasis is moving to the concept of psoriasis as an IL-17A-driven disease. New questions …
The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis.
Sieper J, Poddubnyy D, Miossec P. Sieper J, et al. Nat Rev Rheumatol. 2019 Dec;15(12):747-757. doi: 10.1038/s41584-019-0294-7. Epub 2019 Sep 24. Nat Rev Rheumatol. 2019. PMID: 31551538 Review.
The cytokines IL-23 and IL-17 have an important role in the pathogenesis of, and as a therapeutic target in, both animal models of chronic inflammation and some human chronic inflammatory diseases. The traditional view is that a main source of IL-17
The cytokines IL-23 and IL-17 have an important role in the pathogenesis of, and as a therapeutic target in, both anima …
Targeting IL-17 and TH17 cells in chronic inflammation.
Miossec P, Kolls JK. Miossec P, et al. Nat Rev Drug Discov. 2012 Oct;11(10):763-76. doi: 10.1038/nrd3794. Nat Rev Drug Discov. 2012. PMID: 23023676 Review.
The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, autoimmunity and host defence led to the experimental targeting of these molecules in mouse models of diseases as well as in clinical settings. …
The key role of interleukin-17 (IL-17) and T helper 17 (T(H)17) cells in tissue inflammation, auto …
Anti IL-17 in psoriasis.
Ly K, Smith MP, Thibodeaux Q, Reddy V, Liao W, Bhutani T. Ly K, et al. Expert Rev Clin Immunol. 2019 Nov;15(11):1185-1194. doi: 10.1080/1744666X.2020.1679625. Epub 2019 Oct 16. Expert Rev Clin Immunol. 2019. PMID: 31603358 Review.
The efficacy and safety data from key phase III clinical trials are reviewed here.Expert opinion: By targeting a key mediator of the interleukin-23/T helper 17 pathway, IL-17 antagonists are an effective treatment for plaque psoriasis. ...The efficacy …
The efficacy and safety data from key phase III clinical trials are reviewed here.Expert opinion: By targeting a key mediator of the inte
IL-17 family: cytokines, receptors and signaling.
Gu C, Wu L, Li X. Gu C, et al. Cytokine. 2013 Nov;64(2):477-85. doi: 10.1016/j.cyto.2013.07.022. Epub 2013 Sep 3. Cytokine. 2013. PMID: 24011563 Free PMC article. Review.
The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in host defense against microbial organisms and in the development of inflammatory diseases. ...The proximal adaptor Act1 is a common mediator d …
The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in h …
IL-17 in the lung: the good, the bad, and the ugly.
Gurczynski SJ, Moore BB. Gurczynski SJ, et al. Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L6-L16. doi: 10.1152/ajplung.00344.2017. Epub 2017 Aug 31. Am J Physiol Lung Cell Mol Physiol. 2018. PMID: 28860146 Free PMC article. Review.
Thus, the IL-17/IL-22 axis is important in both responding to, and recovering from, pathogens. ...This review covers the good, bad, and ugly aspects of IL-17 in the lung....
Thus, the IL-17/IL-22 axis is important in both responding to, and recovering from, pathogens. ...This review covers th …
IL-17 for therapy.
Kurschus FC, Moos S. Kurschus FC, et al. J Dermatol Sci. 2017 Sep;87(3):221-227. doi: 10.1016/j.jdermsci.2017.06.010. Epub 2017 Jun 15. J Dermatol Sci. 2017. PMID: 28633806 Review.
The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammatory diseases. ...Ixekizumab and Brodalumab, both also targeting the IL-17 pathway, were also recently approved by the FDA for p …
The cytokine IL-17 is now a target for an array of therapeutic monoclonal antibodies supposed to treat a variety of inflammato …
Systemic effects of IL-17 in inflammatory arthritis.
Beringer A, Miossec P. Beringer A, et al. Nat Rev Rheumatol. 2019 Aug;15(8):491-501. doi: 10.1038/s41584-019-0243-5. Epub 2019 Jun 21. Nat Rev Rheumatol. 2019. PMID: 31227819 Review.
After a brief description of IL-17 and its local effects on joints, this Review focuses on the systemic effects of IL-17 in inflammatory arthritis. ...In skeletal muscle, IL-17 contributes to muscle contractibility defects and weakness. . …
After a brief description of IL-17 and its local effects on joints, this Review focuses on the systemic effects of IL- …
22,471 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback